About the study
Who is conducting the study?
The Academic Centre for Primary Care in Leuven is investigating, in collaboration with 4 other universities, the effects of antiviral medication on Covid-19.
What medication is being used?
Participants in this study will be treated with either camostat, molnupitavir or a placebo. The likelihood of getting camostat or molnupiravir is 2 in 3.
- Camostat |Camostat is a medication that is used for the past 30 years to treat chronic inflammation of the pancreas. There are few side effects associated with this medication.
- Molnupiravir | Molnupiravir is a new medication against COVID-19 with a good safety profile. With this study, we aim to investigate the efficacy of this antiviral drug in the Belgian population.
![](https://cdn.nimbu.io/s/azev7hi/pages/f7srxmd/DawnAntiviralsIcon.jpg?4whnfgf)
“We are investigating whether these antiviral medications can help you recover faster and become less seriously ill.”
Prof. Dr. Ann Van den Bruel, Chief Investigator
The study in brief
- You use the study medication for 5 or 7 days;
- You fill in the diary for 30 days;
- Someone from the study team will contact you by telephone at various time points and visit you at home on day 8
Is participation free of charge?
Participation is entirely without obligation and free of charge. As a participant, you can withdraw from the study at any time.
Contact: +32 492 13 45 32
![](https://cdn.nimbu.io/s/azev7hi/pages/hh48t3t/Logo_s.png?ogd6vuc)
With the support of:
![](https://cdn.nimbu.io/s/azev7hi/assets/KCE.png)